Cancer, Cancer, Metastatic, Cancer of Esophagus, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck, Head and Neck Cancer, Head and Neck Cancer Metastatic, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Carcinoma, Head and Neck Squamous Cell Carcinoma
Conditions
Keywords
cancer, pembrolizumab, tadalafil, cialis, opdivo, immunotherapy, metastatic, carcinoma, pd-1, pde
Brief summary
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Detailed description
Immune competent animal models of HNSCC demonstrate that combination PDE-5 inhibitor (tadalafil) and PD-1 inhibitor therapy is more effective than either therapy alone based on the concept of targeting multiple immune repressive abnormalities simultaneously (PD-1 checkpoint and myeloid suppressive pathways). This trial will test the hypothesis that combination PD-1 inhibition and PDE-5 inhibition can be safely co-administered, and secondarily test the hypothesis that the combination of both therapies will be more effective than PD-1 inhibition alone in recurrent/metastatic HNSCC.
Interventions
DRUGPembrolizumab
200 mg intravenously every 3 weeks
DRUGTadalafil
10 mg by mouth daily
Sponsors
University of California, San Diego
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Selected Inclusion Criteria: * Patients (at least 18 years of age) must have recurrent or metastatic squamous cell carcinoma of the head and neck. * Presence of measurable disease. * Life expectancy of greater than 12 weeks * Patients must have normal organ and marrow function Selected
Exclusion criteria
* Prior therapy with an PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting * Uncontrolled central nervous system metastases (stable metastases permitted) * Active autoimmune disease * Chemotherapy ≤28 days prior to first administration of study treatment and/or monoclonal antibody ≤8 weeks prior to first administration of study treatment. * Prior daily use of tadalafil or other long-acting PDE5 inhibitors for one month or greater within 3 months of trial enrollment * Current use of all other long-acting PDE5 inhibitors. * Known severe hypersensitivity to tadalafil or any of the excipients of this product * Current treatment with nitrates * Current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor such as ketoconazole or ritonavir. * Current treatment with guanylate cyclase (GC) stimulators such as riociguat. * History of hypotension and/or blindness and/or sensorineural hearing loss during prior treatment with tadalafil or other PDE-5 inhibitors * History of known hereditary degenerative retinal disorders, including retinitis pigmentosa * Prior history of non-arteritic anterior ischemic optic neuropathy * Pregnant or breastfeeding; a negative pregnancy test is required within 14 days of randomization for all women of childbearing potential. * History of stroke within prior 6 months. * History of acute myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure * Left ventricular outflow obstructions, such as aortic stenosis and idiopathic hypertrophic subaortic stenosis * Angina requiring treatment with long-acting nitrates * Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration * Unstable angina within 90 days of visit 1 (Braunwald 1989) * Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention * History of any of the following coronary conditions within 90 days of planned tadalafil administration: * Myocardial Infarction * Coronary artery bypass graft surgery * Percutaneous coronary intervention (for example, angioplasty or stent placement) * Any evidence of heart disease (NYHA ≥ Class II as defined in Protocol Attachment LVHG.3) within 6 months of planned tadalafil administration * Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration of \>10 mg/day of prednisone or equivalent) * Prior organ transplantation * Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Dose Limiting Toxicity (DLT) | 2 years | Rate of dose limiting toxicity at least possibly attributable to study treatment |
| Overall Survival (OS) | 12 months | Overall survival at 12 months post-enrollment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Measured by RECIST 1.1 | 12 months | Response measured by RECIST 1.1 |
| Progression Free Survival | 2 years | Progression free survival |
| Adverse Event Rates | 2 years | Adverse event rates |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJoseph Califano
UCSD
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 59.67 years STANDARD_DEVIATION 6.62 |
| Cancer Type Hypopharynx | 1 Participants |
| Cancer Type Larynx | 2 Participants |
| Cancer Type Oral cavity | 2 Participants |
| Cancer Type Oropharynx | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 3 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 3 / 6 |
| other Total, other adverse events | 6 / 6 |
| serious Total, serious adverse events | 1 / 6 |
Outcome results
None listed